Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kendall Hansen

Interventional Pain Medicine Crestview Hills, KY Medical Doctor

NPI 1417952722 CMS profile 109309

340 Thomas More Pkwy, Ste 260, Crestview Hills, KY 41017

Open in the dashboard

General payments

$3,169

175 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kendall Hansen of Crestview Hills, KY is reported in the CMS Open Payments database as having received $3,169 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $18 1
2022 General $42 3
2021 General $1,106 60
2020 General $1,050 60
2019 General $954 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kendall Hansen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Kendall Hansen were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Kendall Hansen Interventional Pain Medicine median Middle half National median
2019 $954 $684 $216–$2,079 $163
2020 $1,050 $382 $122–$1,109 $114
2021 $1,106 $552 $167–$1,554 $132
2022 $42 $605 $187–$1,924 $149
2023 $18 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Teva Pharmaceuticals USA, Inc. $544 25 payments
  2. Collegium Pharmaceutical, Inc. $392 27 payments
  3. Nevro Corp. $301 10 payments
  4. Abbott Laboratories $269 15 payments
  5. Boston Scientific Corporation $221 9 payments
  6. Amgen Inc. $192 12 payments
  7. Medtronic USA, Inc. $168 5 payments
  8. Biodelivery Sciences International, Inc. $139 15 payments
  9. Novartis Pharmaceuticals Corporation $113 6 payments
  10. Medtronic, Inc. $104 5 payments
  11. Other $727 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,169 175 payments
Products named General payments · program years 2019–2023
  1. AJOVY $461 19 payments
  2. XTAMPZA $392 27 payments
  3. AIMOVIG $304 18 payments
  4. Senza Spinal Cord Stimulation System $301 10 payments
  5. Proclaim Family of SCS IPGs $269 15 payments
  6. SPECTRA WAVEWRITER $198 7 payments
  7. KYPHON Balloon Kyphoplasty $156 4 payments
  8. BELBUCA $127 14 payments
  9. RELISTOR $100 7 payments
  10. INTELLIS $87 4 payments
  11. Other $890 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Pain Management: 951

Drug cost

$123

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tizanidine Hcl Generic 22 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record